Who are Goserelin plus Bicalutamide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/goserelin-plus-bicalutamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Goserelin plus Bicalutamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Goserelin plus Bicalutamide (Goserelin plus Bicalutamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen deprivation therapy (combination: GnRH agonist + androgen receptor antagonist). Area: Oncology.

phase 3 Androgen deprivation therapy (combination: GnRH agonist + androgen receptor antagonist) GnRH receptor (goserelin); androgen receptor (bicalutamide) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Goserelin plus Bicalutamide (Goserelin plus Bicalutamide) — Speciality European Pharma Limited. Goserelin suppresses testosterone production via GnRH receptor agonism, while bicalutamide blocks androgen receptor signaling, providing dual hormonal suppression for androgen-dependent cancers.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Goserelin plus Bicalutamide TARGET	Goserelin plus Bicalutamide	Speciality European Pharma Limited	phase 3	Androgen deprivation therapy (combination: GnRH agonist + androgen receptor antagonist)	GnRH receptor (goserelin); androgen receptor (bicalutamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen deprivation therapy (combination: GnRH agonist + androgen receptor antagonist) class)

Speciality European Pharma Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Goserelin plus Bicalutamide — Competitive Intelligence Brief. https://druglandscape.com/ci/goserelin-plus-bicalutamide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab